We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Closed April 13 4:00PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
Last Trade
Last Trade Time
Average Volume (3m)
Financial Volume

PRE Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
PXMDPaxMedica Inc
$ 0.8385
MNDRMobile health Network Solutions
$ 14.87
CNXAConnexa Sports Technologies Inc
$ 1.50
PRZOParaZero Technologies Ltd
$ 1.08
$ 0.09542
MOTSMotus GI Holdings Inc
$ 0.2631
CISSC3is Inc
$ 1.865
LXEHLixiang Education Holding Company Ltd
$ 0.4325
GVHGlobavend Holdings Ltd
$ 1.20
SLNHSoluna Holdings Inc
$ 1.59
SQQQProShares UltraPro Short QQQ
$ 10.89
NKLANikola Corporation
$ 0.7014
$ 0.09542
PXMDPaxMedica Inc
$ 0.8385
AAPLApple Inc
$ 176.55

PRE Discussion

View Posts
TrendTrade2016 TrendTrade2016 8 months ago
TrendTrade2016 TrendTrade2016 8 months ago
Triple nickle Triple nickle 8 months ago
TrendTrade2016 TrendTrade2016 8 months ago
pennyfinder pennyfinder 1 year ago
Canton Fitzgerald overweight rating with $7 target. Go $PRE!
pennyfinder pennyfinder 1 year ago
Looking fishy here
pennyfinder pennyfinder 1 year ago
Did you get back in? The price looks tempting.
makinezmoney makinezmoney 1 year ago
$PRE: Scalped out at 3.20...............

Will look to get in again now that its dipping lower........ now at 2.60

Story isn't done here with that FDA approval.

Looking good

JsTrades JsTrades 1 year ago
Nice almost got there XD
DH112 DH112 1 year ago
ErnieBilco ErnieBilco 1 year ago
makinezmoney makinezmoney 1 year ago
$PRE: IPO Price on May 18,2023 was $8.60 !

So there you go................ a gapfill on the chart is there with this kinda FDA news

makinezmoney makinezmoney 1 year ago
$PRE: Prenetics owns ACT Genomics.....

ACT Genomics received the FDA clearance for ACTOno today.

Looks like gooooooooodddddddddddd news to me.

makinezmoney makinezmoney 1 year ago
$PRE: Now 3.50............ GOOOOOOOOOOOOOOoooooooooooooo

Lets get $10 today !!!!!!!!!!!!!!

Pt3 Pt3 1 year ago
Just chased
makinezmoney makinezmoney 1 year ago
$PRE: Added 10k at $3 !!!!!!!!!!!!!!!

LEtsssssssssss gooooooooooooooo

Looks like there are $290Milly in Sales already


makinezmoney makinezmoney 1 year ago
$PRE: This is PreNetics Global....... Booming to $3 now

CHINESE PLAY !!!!!!!!!!!!!!!!



Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology market
FDA market authorization advances personalized cancer care in Asia
Clearance sets the stage for continued R&D investment into early detection / liquid biopsy
LONDON and HONG KONG, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced that ACT Genomics, a company which Prenetics recently acquired a majority stake in, has received clearance from the U.S. Food and Drug Administration (FDA) for ACTOnco, the company’s comprehensive genomic profiling test for solid tumors. ACTOnco is intended for use by healthcare professionals to help them inform clinical management decisions in accordance with professional guidelines for cancer patients with solid tumors. This is the first and only Asia-based company to receive FDA clearance for a comprehensive genomic profiling test. ACTOnco is a diagnostic test which:

provides a comprehensive genomic profiling test that looks at 440 cancer-associated genes;
provides information to help guide clinical management decisions on the use of targeted oncology therapies, including immunotherapies;
is intended as a pan-cancer test including breast, colon, endometrial, lung, and other cancers;
is an FDA-cleared platform for comprehensive genomic profiling assay development for biopharma companies developing precision therapeutics.
The ability to perform a comprehensive genomic profiling test on an individual tumor helps open the door for personalized medicine, and a future where a person is matched with a treatment that targets the specific weaknesses in his or her cancer.

"Today’s landmark clearance by the FDA represents a significant advancement in personalized cancer care in Asia and may lead to reimbursement and coverage by private insurers and healthcare systems. The clearance by the FDA further validates our status as a pioneer in the industry and we will continue to invest further in R&D efforts, especially related to early detection of cancer in healthy populations,” said Danny Yeung, Chairman of ACT Genomics and Chief Executive Officer of Prenetics.

Dr. Hua Chien Chen, Chief Executive Officer of ACT Genomics, said, “It was a tremendous team and scientific effort to develop ACTOnco. Asia contributes 48% of the new cancer cases and 55% of the cancer deaths in the world. The disease imposes a serious burden on Asia. While precision medicine provides an advantage in disease diagnosis and treatment planning and has become a routine clinical practice in the west, it is not the case in Asia. ACT Genomics is the first biotech company in Asia that received market authorization for a cancer comprehensive genomic profiling assay. Unlike most of the currently marketed tests developed by US companies using mainly clinical samples from Western countries, the ACTOnco assay was developed and validated using half of the Western clinical samples and half of the Asia clinical samples. ACTOnco enables physicians to gain better insights into the genetic underpinnings of each patient’s illness and helps them to formulate the best treatment decisions. Having ACTOnco cleared by the FDA will open new opportunities for patients to get the best cancer care. With this incredible milestone achieved, we will continuously promote precision medicine in Asia and our company mission to turn genomics into action.”

About ACT Genomics

ACT Genomics is an innovation-driven cancer solution provider with offices in Taipei, Hong Kong, Singapore, Tokyo, Bangkok, and the United Kingdom. With its Next-Generation Sequencing (NGS) technology, CAP-accredited laboratories, experienced bioinformatics team, and proprietary AI algorithms, ACT Genomics provides optimal cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, as well as cancer risk assessment services to medical professionals. Its mission is to “Turn Genomics into Action”. To learn more about ACT Genomics, visit

About Prenetics

Founded in 2014, Prenetics is a major global diagnostic and genetic testing company with the mission to bring health closer to millions of people globally and decentralize healthcare by making the three pillars — Consumer Health, Clinical Care and Medical & Cancer Genomics — comprehensive and accessible to anyone, at anytime and anywhere. Prenetics is led by visionary entrepreneur, Danny Yeung, with operations across nine locations, including the United Kingdom, Hong Kong, India, South Africa, and Southeast Asia. Prenetics develops consumer genetic testing and early colorectal cancer screening and provides COVID-19 testing, rapid point of care and at-home diagnostic testing and medical genetic testing. Prenetics is listed on NASDAQ with the ticker PRE. To learn more about Prenetics, visit

Investor Relations Contact:

ICR Westwicke:
Caroline Corner +415 202 5678 Email:

Media contact:
Strategic Public Relations Group
Corinne Ho +852 2114 4911 Email:
Forward-Looking Statements

In addition to historical information, this release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. These statements are based on estimates and forecasts and reflect the views, assumptions, expectations, and opinions of Prenetics and ACT Genomics. Any such estimates and assumptions, expectations, forecasts, views or opinions, whether or not identified in this press release, should be regarded as indicative, preliminary and for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. These statements include, but are not limited to, statements by our management or the board regarding expectations for the closing of the acquisition, statements of plans, objectives, and expectations of synergy between Prenetics and ACT by our management or the board or by ACT or ACT’s management or board. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Because of these uncertainties, you should not make any investment decisions based on our estimates or forward-looking statements. All information provided in this press release is as of the date of this press release. Prenetics does not undertake any obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required under applicable law.

Source: Prenetics Limited
👍️ 1
Penny Roger$ Penny Roger$ 12 years ago
~ $PRE ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $PRE ~ Earnings expected on Monday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.

~ Barchart:
~ OTC Markets:
~ Google Finance:
~ Google Fin Options: h
~ Yahoo! Finance ~ Stats:
~ Yahoo! Finance ~ Profile:
~ BusyStock:
~ CandlestickChart:
~ Investorshub Trades:
~ Investorshub Board Search:
~ Investorshub PostStream Search:
~ Investorshub Goodies Search:
~ Investorshub Message Search:
~ MarketWatch:
~ E-Zone Chart:
~ 5-Min Wind:
~ 10-Min Wind:
~ 30-Min Wind:
~ 60-Min Wind:

*If the earnings date is in error please ignore error. I do my best.
Penny Roger$ Penny Roger$ 12 years ago
PartnerRe Ltd.(PartnerRe) is the ultimate holding company for its international reinsurance group. The Company provides reinsurance on a worldwide basis through its wholly owned subsidiaries, including Partner Reinsurance Company Ltd. (PartnerRe Bermuda), Partner Reinsurance Europe Limited (PartnerRe Europe) and Partner Reinsurance Company of the United States (PartnerRe U.S.). It also offers alternative risk products that include weather and credit protection to financial, industrial and service companies on a worldwide basis. PartnerRe monitors the performance of its operations in three segments: Non-life, Life, and Corporate & Other. The Non-life segment is further divided into four sub-segments, North America, Global (Non-U.S.) Property and Casualty (Global (Non-U.S.) P&C), Global (Non-U.S.) Specialty and Catastrophe.

Your Recent History

Delayed Upgrade Clock